CellMosaic揭开了AqT平台,该平台是一个旨在提高癌症药物精确度和可获得性的技术平台。 CellMosaic unveils AqT platform, a tech aimed at enhancing cancer drug precision and accessibility.

Cell Mosaic是一家得到国防部认可的生物技术公司, 将于1月7日主办一个网络研讨会, CellMosaic, a biotech firm recognized by the Department of Defense, will host a webinar on January 7 to discuss its new technology that could revolutionize cancer treatment. AqT平台帮助癌症药物更精确地针对肿瘤,减少副作用,并有可能使有针对性的疗法更容易获得。 The AqT platform helps cancer drugs target tumors more precisely, reducing side effects and potentially making targeted therapies more accessible. 到2029年,这类药物的全球市场预计将达到400亿美元。 The global market for such drugs is expected to reach $40 billion by 2029.